You are here

  • Home
  • Archive
  • Volume 20, Issue 1
  • Antipsychotic adjunctive therapy to mood stabiliser should be continued for 6 months after remission of a manic episode

Article Text

Article menu
Download PDFPDF
Pharmacological interventions
Antipsychotic adjunctive therapy to mood stabiliser should be continued for 6 months after remission of a manic episode
  1. Kotaro Hatta
  1. Correspondence to Dr Kotaro Hatta, Department of Psychiatry, Juntendo University Nerima Hospital, Tokyo, Japan; khatta{at}juntendo.ac.jp

http://dx.doi.org/10.1136/eb-2016-102532

Statistics from Altmetric.com

    ABSTRACT FROM: Yatham LN, Beaulieu S, Schaffer A, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: a CANMAT randomized double-blind trial. Mol Psychiatry 2016;21:1050–6.OpenUrl

    What is already known on this topic

    Recently, clinical guidelines about treatment of mania have been published by important scientific societies.1 Atypical antipsychotic adjunctive therapy to lithium or valproate is effective in treating acute mania; however, antipsychotics should not be continued unless the benefits of reducing relapse outweigh the risks such as weight gain and metabolic syndrome.2 So far, there is no high-quality evidence for such beneficial duration of the therapy. The study by Yatham and colleagues aimed to determine the efficacy of different durations (24 and 52 weeks) of atypical antipsychotic adjunctive therapy to mood stabiliser versus discontinuing …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/